Wiem Chaabane’s Post

Forrester Pharma: Pioneering Healthcare Solutions for a Healthier South Africa At Forrester Pharma, an AfroCentric Group company, we are driven by a singular mission: to make quality, affordable healthcare accessible to all South Africans. By introducing cost-effective, innovative solutions, we are reshaping the pharmaceutical landscape and improving lives across the country. From rapid generic drug entries to successful product launches, our goal is to bridge the gap between cutting-edge healthcare and the communities that need it most while contributing to reducing the overall cost of healthcare in South Africa. Led by Jerome Smith, a trailblazer in South Africa’s pharmaceutical industry and the visionary behind Cipla Medpro, Forrester Pharma is supported by a highly skilled management team. With decades of collective experience and key partnerships with Governmental and Regulatory Authorities, as well as Healthcare Professionals, we have the strategic advantage to bring world-class pharmaceutical products to market efficiently and effectively, ultimately driving down healthcare costs. Our Vision: We are committed to unlocking our full potential to drive meaningful change in South Africa's healthcare sector. By growing our portfolio of brands, innovating relentlessly and keeping the consumer at the heart of everything we do, we aim to contribute to a healthier, more equitable society while supporting AfroCentric’s strategic goal of making healthcare more affordable and accessible for all. Our Values: · Quality: Ensuring that high-quality healthcare is accessible and affordable to all. · Excellence: Achieving excellence in both product development and service delivery. · Teamwork: Fostering collaboration at every level, with partners, healthcare professionals and customers. · Trust: Building and maintaining strong relationships founded on trust and integrity. Together, we are shaping the future of healthcare in South Africa through diversity, innovation and a steadfast commitment to improving the lives of those we serve, while supporting AfroCentric’s ambition to reduce the cost of healthcare for all South Africans. #HealthcareInnovation #ForresterPharma #PharmaceuticalExcellence #AccessToCare #HealthForAll #InnovationInHealthcare #TrustAndTeamwork #AfroCentricGroup

Middle East and Africa #Pharmaceuticals_Market is thriving due to rising incidences of chronic diseases, increasing investments in #healthcare, a spurring demand for generic drugs, thriving #medical_tourism, regulatory support, and R&D initiatives. 💡As per the recent #market_research_report, 𝐌𝐢𝐝𝐝𝐥𝐞 𝐄𝐚𝐬𝐭 𝐚𝐧𝐝 𝐀𝐟𝐫𝐢𝐜𝐚 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 size by value at USD 49.6 billion in 2023. During the #forecast period between 2024 and 2030, BlueWeave expects Middle East and Africa #Pharmaceuticals Market size to expand at a #CAGR of 6.80% reaching a value of #USD 75.3 #billion by 2030. 🌐𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐭𝐨 𝐁𝐥𝐮𝐞𝐖𝐞𝐚𝐯𝐞 𝐅𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 "𝐌𝐢𝐝𝐝𝐥𝐞 𝐄𝐚𝐬𝐭 𝐚𝐧𝐝 𝐀𝐟𝐫𝐢𝐜𝐚 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥𝐬 𝐌𝐚𝐫𝐤𝐞𝐭" ➖ https://lnkd.in/e2drbdWB ▶ 𝐌𝐚𝐣𝐨𝐫 𝐩𝐥𝐚𝐲𝐞𝐫𝐬: ✔Sanofi, ✔Novartis, ✔Pfizer, ✔Merck Group, ✔Roche, AstraZeneca, ✔Johnson & Johnson, ✔Bayer, ✔TakedaPharmaceutical Nordics AB, ✔AbbVie 📢𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐲 – 𝐆𝐨𝐯𝐞𝐫𝐧𝐦𝐞𝐧𝐭𝐬’ 𝐈𝐧𝐢𝐭𝐢𝐚𝐭𝐢𝐯𝐞𝐬 𝐚𝐧𝐝 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐑𝐞𝐟𝐨𝐫𝐦𝐬 Governments’ supportive initiatives and #healthcare_reforms are projected to drive Middle East and Africa Pharmaceuticals Market significantly. Increasing investments in #healthcare_infrastructure, coupled with policies to enhance access to essential #medicines, are improving #healthcare_delivery. #BlueWeave #Consulting #Marketforecast #Marketresearch #MEAHealthcare #PharmaceuticalIndustry #HealthcareTrends #MedicalInnovation #HealthcareOutlook

#MENA’s #pharmaceutical #market is expected to be worth $52.4 billion by the end of 2024 and could grow to $59.9 billion by 2028, according to Fitch Solutions. This growth potential is being supported by the efforts of several countries to expand their #universal #healthcare #coverage, including #Morocco, which has been implementing major #health system reforms since 2020 and aims to have 100% #health coverage by 2025, according to The World Bank. Having been in the market for over 90 years, Moroccan pharmaceutical company, Cooper Pharma, is playing a role in these big plans. “We’re always looking for opportunities. We plan to reinforce our presence and further grow in our home country and beyond,” says Ayman Cheikh-Lahlou, Chairman and CEO of Cooper Pharma. Cooper Pharma’s business covers both manufacturing and commercial activities, with a network of nine fully-owned pharmaceutical manufacturing sites in the U.A.E., Saudi Arabia, Spain, the Czech Republic, Cote d’Ivoire, Rwanda, and Morocco. The company manufactured around 70 million packets of tablets and vials of medication in 2023, but this is still much less than it can do. Its total capacity stands at 120 million packs, and the CEO is determined to hit the maximum soon. As of 2023, Cooper Pharma had a market share of 11% by units in Morocco, explains Cheikh-Lahlou, as he emphasizes that the company intends to either establish new manufacturing capacities or acquire existing facilities in the near future. #Morocco allocated about $3.1 billion to its #health and social protection sector for 2024, marking a significant 55% increase from the 2021 budget. The government is also linking IT systems and hospitals under the Ministry of Health and Social Protection through a national database as part of a new integrated vision for upgrading the #health system, in line with the commitments of its 2021-2026 government program. To achieve its #healthcare #coverage goals, collaborative efforts have become crucial for Morocco, not only between the country’s government and private sector but also with international institutions. In 2023, The World Bank approved a $450 million program to support the government of #Morocco in implementing its ambitious reforms and help strengthen the #health system in underserved areas. Last year also saw the launch of the #Morocco- World Health Organization cooperation strategy 2023-2027. Marina Hartman Olivella

🔒 𝗨𝗻𝗹𝗼𝗰𝗸𝗶𝗻𝗴 𝘁𝗵𝗲 𝗦𝗮𝘂𝗱𝗶 𝗔𝗿𝗮𝗯𝗶𝗮𝗻 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗠𝗮𝗿𝗸𝗲𝘁: 𝗢𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀 𝗮𝗻𝗱 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗲𝘀🔒 As pharmaceutical companies look to expand their global footprint, Saudi Arabia is becoming an increasingly attractive option, serving as a gateway to the Middle Eastern and North African markets. At Inbeeo, we appreciate that aligning with the Saudi Arabia’s vision2030 and navigating reimbursement pathways will be critical to successful launches in this market. 🌟 𝗩𝗶𝘀𝗶𝗼𝗻 𝟮𝟬𝟯𝟬 𝗮𝗻𝗱 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁: Saudi Arabia’s Vision 2030 plan allocates significant resources to healthcare, focusing on enhancing service access, improving quality, and strengthening preventive measures. This initiative presents an opportunity for pharmaceutical companies to align their strategies with national goals regarding improving healthcare. 🏥 𝗥𝗲𝗶𝗺𝗯𝘂𝗿𝘀𝗲𝗺𝗲𝗻𝘁 𝗣𝗮𝘁𝗵𝘄𝗮𝘆𝘀: •   𝗣𝗿𝗶𝘃𝗮𝘁𝗲 𝗦𝗲𝗰𝘁𝗼𝗿: Price and registration are often sufficient for access, with individual hospitals requesting additional data. •   𝗣𝗮𝗿𝗮𝗹𝗹𝗲𝗹 𝘁𝗼 𝗠𝗮𝗿𝗸𝗲𝘁 𝗔𝘂𝘁𝗵𝗼𝗿𝗶𝘀𝗮𝘁𝗶𝗼𝗻: Early reimbursement and physician engagement can raise product profiles and increase uptake through patient access programmes. •   𝗠𝗶𝗻𝗶𝘀𝘁𝗿𝘆 𝗼𝗳 𝗛𝗲𝗮𝗹𝘁𝗵 (𝗠𝗼𝗛) 𝗖𝗲𝗻𝘁𝗿𝗮𝗹 𝗥𝗲𝗶𝗺𝗯𝘂𝗿𝘀𝗲𝗺𝗲𝗻𝘁: National access is granted through the engagement of the MoH stakeholders, with regional Pharmacy and Therapeutic Committees (P&TCs) evaluating clinical and economic data, leading to the inclusion of the product on the Saudi National Formulary. 📊 𝗨𝗽𝗰𝗼𝗺𝗶𝗻𝗴 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗼𝗲𝗰𝗼𝗻𝗼𝗺𝗶𝗰 𝗘𝘃𝗮𝗹𝘂𝗮𝘁𝗶𝗼𝗻 𝗚𝘂𝗶𝗱𝗲𝗹𝗶𝗻𝗲𝘀: •   𝗟𝗮𝘂𝗻𝗰𝗵𝗶𝗻𝗴 𝗶𝗻 𝟮𝟬𝟮𝟱: These guidelines will mandate the submission of cost and budget impact analyses, with decisions from other influential HTA bodies playing a significant role. •   𝗖𝗼𝘀𝘁-𝗲𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲𝗻𝗲𝘀𝘀 𝘁𝗵𝗿𝗲𝘀𝗵𝗼𝗹𝗱𝘀: SAR 50k-75k (equating to ~£10k-15,500) will be implemented from 2025. Saudi Arabia's strategic initiatives and evolving reimbursement pathways offer a viable opportunity for broadening access to innovative treatment options. By fully understanding the objectives and mechanisms linked to vision2030, companies can navigate the complexities of the market and achieve sustainable success. Written by Katie Hill, our Senior Associate Here at Inbeeo, we can support companies with aligning and developing their launch strategies for Saudi Arabia, with further adaptation to the MENA region. Contact us today! #Pharmaceuticals #Healthcare #SaudiArabia #Vision2030 #MarketEntry #HealthcareInnovation #PharmaGrowth

🩺 Fragile supply chains have led to critical drug shortages worldwide, impacting access to essential healthcare. Strengthening supply chains is therefore crucial to ensuring continuous availability of high-quality, affordable medicines. This highlights the urgent need for a stable and resilient infrastructure to support global healthcare.    Headquartered in Greece, PharOS Ltd specializes in creating generics, OTC and value-added products, with a focus on complex drugs for life-threatening diseases. Through its extensive portfolio of over 100 products and 9,200+ marketing authorizations globally, PharOS actively works to secure access to high-quality, affordable healthcare. The company stands out with its strong focus on innovation and R&D. From patent scouting and dossier development to manufacturing, PharOS accelerates the availability of essential generics, empowering major global pharma partners to meet growing healthcare demands worldwide. 😷 💊 By supporting not only immediate needs but also the wellbeing of future generations, PharOS aligns seamlessly with our purpose of “co-creating living spaces for generations to come.”   We’re proud to support PharOS in their mission to develop robust, local pharmaceutical solutions, paving the way for a healthier, more stable future in global healthcare. 🌱💪   #TeamVi #HealthcareInnovation #SustainableFuture #DrugShortages #SustainableHealthcare

We are organizing a session on Market Access!    As the continent embarks on developing and scaling up its pharmaceutical industries, ARC is focused on coordinating efforts to create markets across the continent and beyond for locally manufactured medicines and health products, leveraging existing platforms such as the Africa Continental Free Trade Area (AfCFTA), to create a single market for the continent and Africa CDC to champion regional manufacturing and other market access efforts.     This session will foster high-level discussions with key stakeholders and partners to get insights into this transformative journey, share knowledge, and define a way forward for coordinated investments and capacity building, whilst also scaling up the enablement and support at the country and regional levels.      Dr Maraki Frike, Director, CHS Advisory  Dr Tom Menge of the Department of Health, Kenya    Learn more about us: https://lnkd.in/ePF378s6  SAPICS #SAPICS2024 #SupplyChainMetamorphosis #SupplyChainConference #CapeTown #supplychainmanagement

Marubeni to Participate in a Major Distributor of Healthcare Products in Africa Summary: Marubeni has concluded an agreement to make a strategic investment into Phillips Healthcare Corporation (hereinafter, “Phillips Pharma”) which provides regulatory, sales and marketing, distribution, and related after-sales services for pharmaceuticals, medical devices, and diagnostics equipment in Sub-Saharan Africa. Under the agreement, Marubeni will support and facilitate the continued growth and expansion of Phillips Pharma in Sub-Saharan Africa.   Phillips Pharma is among the leading sales companies for healthcare products in Africa, and has expanded its business in the region by distributing a wide range of products from over one hundred of the world’s leading healthcare companies through partnerships with these companies. Through this investment, Marubeni will leverage its extensive network among global healthcare companies to support and facilitate Phillips Pharma’s business activities aimed at improving health and wellness standards in Sub-Saharan Africa.   Going Forward: Marubeni has positioned the pharmaceutical business as a focus area among its next generation businesses, and has promoted business expansion through inroads into China, the Middle East, and other regions. In Africa, Marubeni has remained committed to improving the health and living standards of local communities, by means such as an anti-malarial drug development program, and has supported local startups by participating in the AAIC Fund. Marubeni is endeavoring to create and develop new businesses in Africa, and will aim to continuously contribute to solving global healthcare and related issues. Click here to learn more: https://lnkd.in/ghTB5uij Click here for information on Marubeni's Next Generation Business Development Division: https://lnkd.in/gUNQxWxe #Marubeni

Last week, the Foundation’s CEO, Jayasree Iyer, was a guest on CNBC Africa where she spoke about our latest report which examines how pharmaceutical companies are measuring and reporting #PatientReach and sets out practical recommendations that can help accelerate current efforts. Speaking to Tabitha Muthoni, Jayasree emphasised that #pharma companies should be considering the needs of patients and the burden of disease in different communities to determine the real number of patients in need of access to treatments. "If they know the need and they serve communities based on that then we will actually be bridging the gaps in #HealthEquity a lot better." Watch the guest appearance ➡ https://lnkd.in/eqftaChh #PatientCentricity #MeasuringImpact #AccesstoMedicine #EquitableAccess #AccesstoHealthcare #GlobalHealth

Nigeria’s health and pharmaceutical sector experienced major transformations in 2024, driven by policy reforms, increased investment, and strategic collaborations. The government introduced new frameworks to enhance local pharmaceutical production, improve regulatory oversight, and strengthen supply chains, with Lagos State leading initiatives for state-controlled drug manufacturing. Significant investments, such as Lagos’ $46 million Cancer and Diagnostic Institute and NAFDAC’s 5-Year Traceability Plan, underscored efforts to enhance healthcare infrastructure and combat counterfeit medicines. Public-private partnerships played a crucial role, with USAID supporting Swipha in obtaining WHO prequalification for key medicines, and Fidson Healthcare’s collaboration with Chinese firms aimed to boost local drug manufacturing. The year also saw global health advancements influencing Nigeria, including WHO’s $1.7 billion investment round and its partnership with TikTok to tackle health misinformation. In this Health Sector Round-up and 2025 forecast, our Associates, Emmanuel Ughanze, Oluchukwu Gospel Nwakor, Babatunde Oyewole, and Confidence James, examine the impact of these regulatory reforms, investment trends, and international partnerships on Nigeria’s healthcare landscape. They highlight how policy shifts are shaping local pharmaceutical production, assess the effectiveness of supply chain enhancements, and explore strategies for aligning with global best practices to improve healthcare delivery in Nigeria. Click the link below to read the full publication and reach out to contact@strenandblan.com for further inquiries and consultation. https://lnkd.in/d8G7n2aA #strenandblanpartners #healthsector #worldhealthorganisation

Collaboration is at the heart of everything we do. Ensuring that our medicines reach the people who need them most is not just a responsibility—it is a shared mission. Behind every treatment that improves a patient’s life stands a vast network of professionals whose dedication and expertise make this possible. We deeply value our partnerships with distributors, healthcare providers, and all stakeholders who contribute to making healthcare accessible and efficient. Today, we had an energizing and inspiring meeting with the exceptional team of Alliance Healthcare Romania, one of the leading pharmaceutical distributors in the country. Together, we discussed our vision and strategic projects for 2025, reinforcing our joint commitment to enhancing supply chain efficiency, ensuring continuity in patient care, and driving further innovation in pharmaceutical distribution. This partnership is a testament to how collaboration and shared goals lead to better healthcare outcomes. We are grateful for the passion, expertise, and dedication that our partners bring to the table, making a real impact in the lives of patients. As we look ahead to 2025, we are excited about the opportunities to strengthen our collaborations and continue delivering value to the healthcare ecosystem. A big thank you to the Alliance Healthcare Romania team for their continuous support, professionalism, and shared commitment to making a difference in the pharmaceutical landscape. We look forward to turning today’s discussions into impactful actions! #Collaboration #Healthcare #AllianceHealthcare #Partnerships #PharmaceuticalDistribution #2025Vision